Maresin 2 (macrophage mediator in resolving inflammation 2) is a specialized pro-resolving mediator biosynthesized from DHA via the 12-LOX pathway in activated macrophages. MaR2 orchestrates the active termination of inflammation through enhanced efferocytosis, reduced neutrophil infiltration, M2 macrophage polarization, tissue regeneration, and resolution of inflammatory pain. Unlike passive anti-inflammatory agents that merely suppress inflammation, MaR2 actively drives the resolution program—clearing debris, restoring barrier function, and returning tissue to homeostasis.
Imagine a battlefield after a fierce fight. The enemy (pathogens) is defeated, but the field is littered with destroyed equipment, debris, and fallen soldiers. Without active cleanup, the battlefield remains unusable—crops can't be planted, roads can't be rebuilt. MaR2 is like the specialized cleanup crew that arrives once the fighting stops.
This crew doesn't just sweep things under the rug. They have three critical jobs: First, they signal the remaining fighters (neutrophils) to stand down and leave the area—no more reinforcements needed. Second, they send in specialized "clean-up trucks" (M2 macrophages) that efficiently remove all the debris and dead cells through a process like vacuum-sealed collection (efferocytosis). Third, they activate the reconstruction team—bringing in materials and blueprints to rebuild damaged structures (tissue regeneration). They even turn off the pain alarms that were ringing during the battle, so the area can return to normal function.
Critically, this cleanup crew is made ON-SITE from materials stored in the local warehouse (DHA in cell membranes). The battlefield commanders (macrophages) convert stored supplies into these cleanup signals exactly when and where they're needed. If the warehouse is empty (low DHA status), the cleanup can't happen efficiently—and the battlefield remains inflamed, painful, and dysfunctional indefinitely.
Biosynthesis Pathway:
DHA (22:6n-3) in membrane phospholipids → 12-LOX → 13S-hydroperoxy-DHA → MaR2 (13R,14S-dihydroxy-DHA)
The complete biosynthetic cascade occurs primarily in M2-polarized macrophages during the resolution phase (12-24 hours post-inflammatory initiation):
graph TD
A[Membrane DHA] -->|PLA2| B[Free DHA]
B -->|12-LOX| C[13S-hydroperoxy-DHA]
C -->|Enzymatic conversion| D[MaR2 13R,14S-dihydroxy-DHA]
D --> E[GPCR binding]
E --> F1[Enhanced efferocytosis]
E --> F2[Neutrophil clearance]
E --> F3[M2 polarization]
E --> F4[Pain resolution]
E --> F5[Tissue regeneration]
F1 --> G[Resolution program activation]
F2 --> G
F3 --> G
F4 --> G
F5 --> G
G --> H[Restored homeostasis]
Receptor-Mediated Actions:
MaR2 acts through G protein-coupled receptors (specific receptor still under investigation, likely orphan GPCR). Upon receptor binding:
-
Efferocytosis Enhancement: MaR2 → GPCR activation → PKA pathway → enhanced macrophage expression of engulfment receptors (MerTK, Tim-4) → increased recognition and phagocytosis of apoptotic neutrophils → prevention of secondary necrosis and continued inflammation
-
Neutrophil Regulation: MaR2 → reduced CXCL1 and IL-8 production → decreased neutrophil chemotaxis → shortened Resolution interval (Ri) → typically reduces neutrophil infiltration by 40-60% within 4-6 hours
-
Macrophage Polarization: MaR2 → STAT6 and PPARγ activation → M2 phenotype induction → increased production of IL-10, TGF-beta, and tissue repair factors → suppression of NF-kB → reduced TNF-α, IL-1β, IL-6 production
-
Pain Resolution: MaR2 → reduced TRPV1 and TRPA1 expression in dorsal root ganglia → decreased Substance P and CGRP release → inhibition of COX-2 in spinal cord → resolution of inflammatory hyperalgesia within 2-4 hours (in animal models)
-
Tissue Regeneration: MaR2 → upregulation of growth factors (VEGF, TGF-beta) → enhanced angiogenesis → collagen deposition → restoration of barrier integrity → accelerated wound closure (typically 30-50% faster in DHA-replete states)
Antimicrobial Defense:
MaR2 maintains host defense during resolution by:
- Enhancing bacterial phagocytosis (not suppressing it)
- Increasing ROS production in response to pathogens
- Promoting antimicrobial peptide synthesis
- Supporting neutrophil extracellular trap formation when pathogens present
This "resolution without immunosuppression" is evolution's solution to preventing chronic inflammation while maintaining vigilance against secondary infection.
Metabolic Inactivation:
MaR2 is metabolically inactivated by eicosanoid oxidoreductase and dehydrogenases → conversion to 13-oxo-MaR2 (inactive) → ensures temporal control of resolution signaling (half-life approximately 15-30 minutes in vivo)
Patient Populations:
MaR2 deficiency (functional or absolute) is clinically relevant in:
- Chronic inflammatory conditions: Patients with rheumatoid arthritis, inflammatory bowel disease, chronic pain, periodontitis—often show impaired SPM production and prolonged resolution interval
- Omega-3 deficiency states: Omega-3 index <4% correlates with low maresin biosynthetic capacity
- Metabolic syndrome patients: Obesity-associated inflammation impairs 12-LOX function and maresin synthesis
- Post-surgical recovery: Delayed wound healing correlates with low SPM profiles
- Chronic pain syndromes: Fibromyalgia, osteoarthritis, neuropathic pain—resolution failure perpetuates pain signaling
Metamodel Integration:
-
Metamodel 0 (Evolutionary): Maresins represent evolution's solution to the trade-off between effective pathogen defense and tissue preservation. Modern low DHA diets (evolutionary mismatch) impair this ancient resolution machinery.
-
Metamodel 1 (Selfish Systems): The selfish immune system perpetuates inflammation when resolution signals are absent—MaR2 deficiency allows immune cells to continue consuming resources (glucose, amino acids) indefinitely. The selfish brain experiences continued pain signaling when maresins fail to reset nociceptor sensitivity.
-
Metamodel 3 (Chronic Low-Grade Inflammation): Impaired maresin synthesis is both consequence and cause of metaflammation—low DHA → poor resolution → sustained inflammation → further membrane DHA depletion → resolution failure cycle
Clinical Thresholds:
- Omega-3 index >8% optimal for SPM biosynthesis
- DHA:AA ratio >1:3 supports adequate maresin production
- Serum maresin levels <5 pg/mL associated with delayed resolution (research threshold)
- Resolution interval (Ri) >48 hours suggests SPM insufficiency
Intervention Implications:
- High-dose DHA supplementation: 2-4g DHA daily to restore substrate availability—emphasize DHA over EPA for maresin synthesis
- 12-LOX cofactor support: Vitamin B6, iron, selenium required for enzyme function
- Reduce competing pathways: Lower arachidonic acid intake to favor DHA metabolism
- Timing consideration: SPM production peaks during resolution phase (12-48 hours post-injury)—early high-dose omega-3 loading before planned procedures
- Combination with aspirin: Low-dose aspirin (81mg) triggers production of aspirin-triggered maresins (AT-MaR) through acetylated COX-2
- Address metabolic blocks: Insulin resistance and obesity impair 12-LOX—metabolic optimization enhances endogenous SPM synthesis
Exam-Relevant Clinical Pearl:
The presence or absence of effective resolution signaling (including MaR2) determines whether acute inflammation transitions to chronic disease. Patients presenting with "treatment-resistant" inflammation often have resolution failure, not treatment-resistant initiation. This reframes intervention from continuous immune suppression to resolution support.
- Biosynthesized from DHA via 12-LOX in M2-polarized macrophages during resolution phase
- Structural formula: 13R,14S-dihydroxy-docosa-4Z,7Z,9E,11E,16Z,19Z-hexaenoic acid
- Acts through orphan G protein-coupled receptors (specific receptor identity still under investigation as of current research)
- Peak endogenous production occurs 12-24 hours after inflammatory stimulus initiation
- Reduces neutrophil infiltration by 40-60% within 4-6 hours in experimental models
- Half-life approximately 15-30 minutes due to rapid eicosanoid oxidoreductase metabolism
- More metabolically stable than some other SPMs (less susceptible to β-oxidation than E-series resolvins)
- Maintains antimicrobial defense while promoting resolution—does not suppress pathogen clearance
- Requires adequate DHA substrate (omega-3 index >8%) and 12-LOX cofactors (B6, iron, selenium)
- Resolves inflammatory pain by reducing TRPV1 expression and COX-2 signaling in nociceptive pathways
- Clinical maresin levels <5 pg/mL associated with impaired resolution capacity
- Aspirin triggers production of aspirin-triggered maresin analogs through COX-2 acetylation
- Maresins — MaR2 is a member of the maresin family of specialized pro-resolving mediators
- MaR1 — structurally and functionally related maresin with similar but distinct receptor profile
- Specialized pro-resolving mediators (SPMs) — MaR2 belongs to this superfamily of lipid mediators that actively terminate inflammation
- DHA — docosahexaenoic acid serves as the essential biosynthetic precursor for all maresins
- 12-LOX — 12-lipoxygenase enzyme responsible for converting DHA to MaR2
- Efferocytosis — MaR2 potently enhances macrophage clearance of apoptotic cells, preventing secondary necrosis
- Resolution interval — MaR2 shortens the Ri by accelerating neutrophil clearance and debris removal
- M2 macrophages — MaR2 promotes M2 polarization, creating a positive feedback loop for resolution
- Omega-3 fatty acids — dietary omega-3 status determines maresin biosynthetic capacity
- Lipid mediator class switching — MaR2 represents the resolution phase in temporal lipid mediator progression
- Chronic inflammation — impaired maresin synthesis perpetuates non-resolving inflammation
- Inflammatory pain — MaR2 resolves hyperalgesia through TRPV1 and COX-2 modulation
- Neutrophil — MaR2 reduces neutrophil infiltration and promotes their clearance from inflamed tissue
- IL-10 — MaR2-activated M2 macrophages produce this anti-inflammatory cytokine
- NF-kB — MaR2 suppresses this pro-inflammatory transcription factor in macrophages
- COX-2 — MaR2 reduces COX-2 expression in pain pathways; aspirin-acetylated COX-2 produces AT-MaR
- Resolvins — related SPM family; maresins and resolvins work synergistically in resolution programs
- Protectins — another DHA-derived SPM family that complements maresin actions
- Arachidonic acid — competes with DHA for enzymatic conversion; high AA:DHA ratio impairs maresin synthesis
- Metabolic syndrome — obesity-associated inflammation impairs 12-LOX function and maresin production
- Wound healing — MaR2 accelerates tissue repair and barrier restoration
- TRPV1 — MaR2 downregulates this pain receptor in sensory neurons
- Fibromyalgia — resolution failure and low SPM profiles common in chronic pain conditions
- Rheumatoid arthritis — impaired maresin synthesis contributes to non-resolving joint inflammation
- Inflammatory bowel disease — mucosal resolution deficiency; maresin levels inversely correlate with disease activity
- VEGF — MaR2 upregulates vascular endothelial growth factor for tissue regeneration
- TGF-beta — MaR2 enhances transforming growth factor-beta for wound healing and fibrosis resolution